ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs–threshold doses for tissue reactions in a …
FA Stewart, AV Akleyev, M Hauer-Jensen, JH Hendry… - Annals of the ICRP, 2012 - Elsevier
This report provides a review of early and late effects of radiation in normal tissues and
organs with respect to radiation protection. It was instigated following a recommendation in …
organs with respect to radiation protection. It was instigated following a recommendation in …
[PDF][PDF] Filgrastim for the treatment of hematopoietic acute radiation syndrome
AM Farese, TJ MacVittie - Drugs Today (Barc), 2015 - researchgate.net
SUMMARY The US Food and Drug Administration (FDA) recently approved
Neupogen®(filgrastim) for the treatment of patients with radiation-induced …
Neupogen®(filgrastim) for the treatment of patients with radiation-induced …
The ability of filgrastim to mitigate mortality following LD50/60 total-body irradiation is administration time-dependent
AM Farese, CR Brown, CP Smith, AM Gibbs… - Health …, 2014 - journals.lww.com
The identification of the optimal administration schedule for an effective medical
countermeasure is critical for the effective treatment of individuals exposed to potentially …
countermeasure is critical for the effective treatment of individuals exposed to potentially …